Infant Bacterial Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Infant Bacterial Therapeutics has a total shareholder equity of SEK153.5M and total debt of SEK0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are SEK207.9M and SEK54.4M respectively.
Key information
0%
Debt to equity ratio
SEK 0
Debt
| Interest coverage ratio | n/a |
| Cash | SEK 191.76m |
| Equity | SEK 153.52m |
| Total liabilities | SEK 54.39m |
| Total assets | SEK 207.92m |
Recent financial health updates
Will Infant Bacterial Therapeutics (STO:IBT B) Spend Its Cash Wisely?
Mar 28
Will Infant Bacterial Therapeutics (STO:IBT B) Spend Its Cash Wisely?
Dec 05We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth
Aug 02Infant Bacterial Therapeutics (STO:IBT B) Is In A Good Position To Deliver On Growth Plans
Apr 03Here's Why We're Not Too Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Situation
Sep 16We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth
May 11Recent updates
It Looks Like Infant Bacterial Therapeutics AB (publ)'s (STO:IBT B) CEO May Expect Their Salary To Be Put Under The Microscope
May 02Will Infant Bacterial Therapeutics (STO:IBT B) Spend Its Cash Wisely?
Mar 28Will Infant Bacterial Therapeutics (STO:IBT B) Spend Its Cash Wisely?
Dec 05We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth
Aug 02Infant Bacterial Therapeutics AB (publ)'s (STO:IBT B) CEO Compensation Is Looking A Bit Stretched At The Moment
May 02Infant Bacterial Therapeutics (STO:IBT B) Is In A Good Position To Deliver On Growth Plans
Apr 03Here's Why We're Not Too Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Situation
Sep 16We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth
May 11We're Not Very Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Rate
Sep 23We're Hopeful That Infant Bacterial Therapeutics (STO:IBT B) Will Use Its Cash Wisely
Apr 07We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth
Dec 15We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth
Aug 25We're Not Very Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Rate
May 06Anthon Jahreskog Just Bought A Sprinkling of Shares In Infant Bacterial Therapeutics AB (publ) (STO:IBT B)
Feb 07Financial Position Analysis
Short Term Liabilities: IBT B's short term assets (SEK199.2M) exceed its short term liabilities (SEK54.4M).
Long Term Liabilities: IBT B has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: IBT B is debt free.
Reducing Debt: IBT B has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IBT B has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: IBT B has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 17.1% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/13 11:21 |
| End of Day Share Price | 2025/05/13 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Infant Bacterial Therapeutics AB (publ) is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.